Vivani Medical Reports $6.8 Million Net Loss in Q1 2026, Increases R&D Spending

Vivani Medical, Inc. reported a net loss of $6.8 million for the first quarter of 2026, compared to a net loss of $6.3 million in the same period of the previous year. The company's operating expenses increased to $6.8 million from $6.6 million year-over-year, driven primarily by a rise in research and development costs, which reached $4.4 million, up from $4.2 million. General and administrative expenses also saw a slight increase, totaling $2.4 million compared to $2.3 million in the prior year. The company's cash and cash equivalents rose to $19.7 million as of March 31, 2026, up from $16.2 million at the end of 2025, reflecting successful capital-raising efforts.

In terms of strategic developments, Vivani Medical has been actively pursuing funding through various equity transactions. During the first quarter of 2026, the company issued 5.2 million shares under its 2025 Private Sales Transactions, generating approximately $5.7 million in gross proceeds. Additionally, a registered direct offering in January 2026 brought in about $2.2 million after expenses. The company is also preparing for the potential spin-off of its subsidiary, Cortigent, which focuses on neurostimulation technologies, although the timeline and terms of this spin-off remain uncertain.

Operationally, Vivani Medical is focused on advancing its product pipeline, which includes several miniature, ultra-long-acting drug implant candidates utilizing its proprietary NanoPortal technology. The company is currently developing NPM-139, a GLP-1 implant for chronic weight management, and NPM-133, a similar product for type-2 diabetes. The company plans to initiate clinical trials for these candidates in mid-2026. As of March 31, 2026, Vivani Medical had a total of 84.6 million shares outstanding, reflecting its ongoing efforts to raise capital and expand its operations.

Looking ahead, Vivani Medical anticipates continued operating losses as it invests in research and development to advance its product candidates. The company has indicated that it expects to incur significant expenses related to clinical trials and regulatory approvals. While it estimates that its current cash reserves will support operations through mid-2027, the company acknowledges the need for additional financing to sustain its business objectives. The ability to secure such funding remains uncertain, and failure to do so could impact the company's development plans and overall financial health.